LG Chem, Ltd

Knowledge

HYRUAN Plus Inj.

Product Profile

Apply for Sample

Chemical ID: CAS Formula HS Code Database

Product Identification

Property Details Manufacturer’s Technical Commentary
Product Name HYRUAN Plus Inj. The marketed product typically contains injectable-grade hyaluronic acid, selected for its specific rheological and biocompatibility properties relevant to medical device and pharmaceutical applications.
IUPAC Name Poly(β-(1→4)-N-acetyl-D-glucosamine-(1→3)-β-D-glucuronic acid) IUPAC nomenclature for sodium hyaluronate reflects the repeating disaccharide unit. Degree of polymerization and salt form may shift based on application (ophthalmic, articular, dermal), which are controlled at process scale.
Chemical Formula (C14H21NO11Na)n The empirical formula is applied to the sodium salt form of hyaluronic acid, which dominates in injectable products. The polymer’s molecular weight range, dictated by fermentation and purification conditions, impacts viscosity and clinical use suitability.
Synonyms & Trade Names Sodium hyaluronate, Hyaluronic acid sodium salt, HA, Hyaluronan, HYRUAN, HYRUAN Plus Injection Manufacturers refer to material as sodium hyaluronate (USP/EP/JP grade or device specification). Synonyms vary by pharmacopoeial standard and device registration file. Trade name aligns with product configuration, molecular weight class, and formulation (cross-linked, linear, or blended types).
HS Code & Customs Classification 3006.30 Assigned in accordance with harmonized customs schedules for “other pharmaceutical goods.” Classifications are finalized by reviewing intended use (e.g., medical device), degree of processing, and composition. Differences in regional coding exist if classified as bulk material or finished preparation.

Production Commentary & Technical Rationale

Raw material selection for HYRUAN Plus Inj. centers on highly pure fermentation-derived sodium hyaluronate. Endotoxin and protein levels are constrained by stringent release standards, since injectable applications mandate minimal immunogenic risk. Bacterial strain selection and growth media formulation affect molecular weight distribution—a parameter managed by batch process controls and downstream fractionation.

The final injectable product’s consistency is not just a factor of bulk hyaluronate quality, but also the cross-linking chemistry (if any), buffer composition, and aseptic filling technology. Molecular weight and cross-link density influence rheological behavior, which in turn affects injectability and tissue persistence. Aqueous solutions emphasize careful control of pH and osmolality, benchmarked against application-specific guidance for intra-articular, dermal, or ophthalmic routes.

Impurity management strategies use multi-stage filtration, ultrafiltration/diafiltration, and depyrogenation to reach required specifications. Process validation includes in-process testing for residual solvents, endotoxins, and microbial limits. Release is governed by pharmacopoeial monograph alignment, with internal test limits defined tighter than compendial minimums, often monitored by GPC for molecular weight profiling and by particle-counting for injectable clarity validation.

Handling, storage, and distribution rely on cold chain controls (2–8°C or ambient, by formulation) and packaging integrity. Solution viscosity may shift under mechanical or thermal stress, so specification of allowable shelf-life and in-use period remains application-dependent and is supported by ongoing stability testing.

Technical Properties, Manufacturing Process & Safety Guidelines
HYRUAN Plus Inj.

Physical & Chemical Properties

Physical State & Appearance

HYRUAN Plus Inj. presents as a sterile, viscoelastic solution. This injectable form is clear and colorless, based on sodium hyaluronate. No perceptible odor is present. Visual consistency across batches indicates successful hydration and correct molecular weight range during production. Variations in solution clarity or color signal issues in purification or sterilization processes.

Melting Point, Boiling Point, Flash Point, Density

Sodium hyaluronate, as a hydrated polymer in aqueous solution, does not possess a definite melting or boiling point. Its density depends on the polymer concentration; higher concentrations increase viscosity and perceived density. These physical attributes remain grade specific and are typically adjusted during upstream formulation, guided by end-use injection parameters and target viscoelasticity.

Chemical Stability & Reactivity

HYRUAN Plus Inj. demonstrates reliable stability under recommended storage conditions. pH adjustment and controlled temperature prevent hydrolytic or oxidative degradation of the polymer chain. Reactivity issues typically relate to high temperatures or direct exposure to oxidizing agents—screening raw materials for peroxide content and monitoring residual solvents minimizes instability. Ultra-high shear and temperature deviations during mixing can introduce chain scission, negatively affecting solution performance and shelf life.

Solubility & Solution Preparation

Sodium hyaluronate readily dissolves in water under controlled mixing to avoid lump formation and molecular damage. Solution behavior depends heavily on the grade’s molecular weight and salt form. Deviations in solubility profile indicate contamination or improper pH during neutralization. Filtration through appropriate membranes removes insoluble particulates before final sterilization and filling.

Technical Specifications & Quality Parameters

Specification Table by Grade

Specifications reflect the grade, target application, and customer standards. For injection use, performance parameters like viscosity, molecular weight distribution, and residual endotoxin levels must fall within narrow, validated windows. Release quality often depends on batch-to-batch reproducibility and established pharmacopoeial or internal acceptance criteria. Detailed cutoffs for impurity levels are tailored during grade development and subject to ongoing review based on customer feedback and regulatory updates.

Impurity Profile & Limits

Common impurities include protein residuals, DNA fragments, and bacterial endotoxins, originating from source material and process streams. Impurity removal leverages multi-step purification: repeated filtration, precipitation, and ultrafiltration. Limits are guided by pharmacopeial standards when available; ongoing surveillance through validated analytical methods ensures that released batches remain compliant with evolving requirements.

Test Methods & Standards

Typical assays include gel permeation chromatography (molecular weight distribution), viscosity measurement under defined shear, and analytical quantification of proteins, nucleic acids, and endotoxins. These methods are validated internally and referenced to standards in pharmacopoeias or industry guidelines. Test frequency and acceptance bands adapt to process capability and cumulative compliance outcomes.

Preparation Methods & Manufacturing Process

Raw Materials & Sourcing

Source selection for sodium hyaluronate uses pharmaceutical-grade hyaluronic acid, with strict traceability—often derived from microbial fermentation or animal tissue, subject to regional regulatory preferences. Key sourcing decisions weigh bio-burden, cross-contamination risk, and quality of the upstream isolation process. Routine auditing of suppliers and raw material lots underpins consistent downstream results.

Synthesis Route & Reaction Mechanism

Fermentative production dominates modern processes due to impurity control and scalability. Controlled enzymatic hydrolysis or chemical modification may adjust polymer chain lengths to target viscosities. All processing steps undergo careful pH and temperature monitoring, minimizing unwanted by-product formation. Neutralization and stabilization employ standardized buffers compatible with parenteral administration.

Process Control & Purification

Critical control points center on seed quality, fermentation conditions, and downstream purification. Inline monitoring of viscosity and conductivity guides step-up interventions. Endotoxin and protein removal efficiency determine acceptability; sequential filtration, dialysis, and sometimes chromatography achieve targeted purity grades. Final sterile filtration and aseptic filling mitigate particulate and microbial contamination.

Quality Control & Batch Release

Release criteria draw on comprehensive analytical results, including molecular weight, rheological properties, purity, bioburden, and endotoxin content. Each lot undergoes identity and sterility confirmation. Quality parameters are not limited to internal targets but factor in customer feedback and field surveillance data, updating specifications as warranted by performance or regulatory changes.

Chemical Reactions & Modification Potential

Typical Reactions

Sodium hyaluronate demonstrates reactivity toward acid-base conditions, oxidizing agents, and certain enzymes. Depolymerization or crosslinking reactions can alter physicochemical properties—these pathways underpin development of derivatives or modified viscosupplements. Adverse reactions often originate during storage under incompatible conditions or uncontrolled mixing with other pharmaceutical agents.

Reaction Conditions (Catalyst, Temperature, Solvent)

Modification reactions depend on catalyst selection and environmental controls. Acid or base catalysis may adjust molecular weight; oxidation—if not strictly controlled—can degrade the polymer. Water acts as the principal solvent—any deviation from pharmaceutical water quality risks final product contaminant levels. All such interventions require validated risk assessments to avoid introduction of process-related impurities.

Derivatives & Downstream Products

Derivatization expands product function, but only after rigorous pre-formulation and toxicity studies. The facility’s process engineers develop and validate conditions for these modifications based on target properties and regulatory acceptability. New grades emerge from this workflow, each with a redefined impurity profile and testing protocol.

Storage & Shelf Life

Storage Conditions (Temperature, Humidity, Light Avoidance, Gas Protection)

HYRUAN Plus Inj. requires controlled cold storage to check degradation velocity. High humidity, extreme temperature swings, and direct light accelerate chain breakdown and compromise sterility. The formulation’s water content and absence of stabilizing agents call for refrigerated conditions unless otherwise validated. Vacuum-sealed, light-impermeable packaging reduces oxidative burden and UV-driven decomposition risk.

Container Compatibility

Compatibility studies guide primary packaging selection—usually medical-grade glass or appropriate polymers. Extractables and leachables testing benchmarks container safety. Differences in packaging approach result from specific regional or customer requirements.

Shelf Life & Degradation Signs

Shelf life depends on formulation ingredients, batch sterility, and storage compliance. Indicators of degradation include turbidity, color change, solution separation, or unusual odor. Products showing instability features are recalled and scrapped as part of ongoing surveillance and pharmacovigilance.

Safety & Toxicity Profile

GHS Classification

HYRUAN Plus Inj. occupies a favorable toxicological profile, as sodium hyaluronate is inherently biocompatible. Highly purified injectable grades do not generally receive GHS hazard classification based on tested exposure scenarios in clinical contexts. Lower grade or industrial material may require safety flags, depending on extractable protein, contaminant, or cross-species origin content.

Hazard & Precautionary Statements

Handling within manufacturing follows strict aseptic technique and personal protective equipment use due to endotoxin and particulate control imperatives. Process deviations or container damage during filling can trigger product recall due to loss of sterility assurance. Waste streams undergo validated decontamination prior to disposal. Facility-level procedures routinely update based on risk assessment and adverse event reporting.

Toxicity Data, Exposure Limits & Handling

Clinical grade hyaluronate features low toxicity by all relevant exposure routes when processed to pharmacopoeial purity. Exposure limits tend to reference initial raw material safety profiles—operator exposure remains minimal given enclosed production and automated filling processes. Continuous personnel training and batch review meetings enforce compliance with GMP and modern risk management frameworks.

HYRUAN Plus Inj.: Supply Capacity, Commercial Terms & 2026 Price Trend Forecast

Supply Capacity & Commercial Terms

Production Capacity & Availability

HYRUAN Plus Inj. production aligns with stringent biopharmaceutical standards. Manufacturing relies on microbial fermentation for hyaluronic acid, followed by purification, sterilization, and packaging under controlled environment conditions. Annual output depends on reactor scale, culture yields, and downstream processing throughput. Output varies year-to-year based on fermentation efficiency and process run rates. Dedicated lines are subject to maintenance and shutdowns for scheduled quality checks and regulatory inspections, which can influence short-term availability.

Lead Time & MOQ

Lead time reflects upstream availability of pharmaceutical-grade raw materials and validated batch release cycles. Typical lead time to ex-works (EXW) dispatch depends on batch size, validation status, and final packaging requirements. Orders during periods of heightened demand or regulatory batch requalification may extend fulfillment windows. Minimum order quantities are set according to sterile line batch size and customer-specific packaging needs. MOQs can be adjusted in consultation with hospital networks and institutional buyers.

Packaging Options

Packaging format is driven by clinical end-use and market regulations: sterile syringes, single-dose vials, or ampoules. Choice affects cold chain stability, handling hazard, and secondary packaging requirements. Outer carton specifications and tamper-evidence are defined per regional compliance. Sterile barrier integrity remains a release-critical attribute. Bulk non-sterile shipments for compounding or reformulation are available for regulatory-accepted customers on special arrangement.

Shipping & Payment Terms

Shipping terms are based on Incoterms and prevailing transit regulations. Active cold chain logistics are mandatory for all finished sterile lots. Risk-management measures incorporate route validation, temperature loggers, and insurance. Payment structure is contract-dependent: institutional sales favor open-account arrangements, while export shipments may default to LC or prepayment arrangements. Bank transfer is standard; alternative payment routes may be discussed for strategic accounts.

Pricing Structure & Influencing Factors

Interpretation of Raw Material Cost Composition

Material cost composition for HYRUAN Plus Inj. links directly to the pharmaceutical-grade fermentation media, microbial strain performance, and quality of primary reagents. Enzymes, nutrients, and purification consumables represent primary contributors. Fluctuations occur due to seasonal supply cycles for sugar sources, fermentation additives, and global price movements for bioprocess inputs. International trade policies targeting critical starting materials have downstream price effects.

Causes of Raw Material Price Fluctuation

Cost volatility in hyaluronic acid production emerges from three angles:

  • Global supply chain risk: Bioprocess reagent disruptions—e.g., due to plant closure, export controls, or pandemic effects.
  • Biotech-grade input quality: Qualification cycles for new reagent lots, impurity profiles, or source traceability can prompt sudden price shifts.
  • Energy and labor: Fermentation and downstream processing remain energy-intensive, with energy price surges passing directly into unit cost.

Price Difference: Grade, Purity, Packaging, Certification

Finished product price gives strongest weight to hyaluronic acid purity, the stringent profile for endotoxin, and residual host cell protein specifications. Clinical-grade batches certified to medical device or pharmaceutical standards command premium multiples to food or cosmetic grades. Regulatory documentation, product registration (EU MDR, FDA DMF), and serial batch traceability add layers to pricing logic. Packaging options such as prefilled syringes or unit-dose vials further affect final invoice. Bulk format for further downstream compounding tends to reflect lower per-unit pricing but brings added qualification criteria and audit requirements.

Global Market Analysis & 2026 Price Trend Forecast

Global Supply & Demand Overview

Production volumes for injectable hyaluronic acid remain concentrated in GMP-certified facilities in Korea, Japan, Western Europe, and select regions of China. Clinical demand rises with expansion of OA (osteoarthritis) patient populations, regulatory acceptance of viscosupplementation, and aging demographics. Cosmetic and regenerative medicine end-uses bring incremental demand, especially in Asia and North America.

Key Economies Analysis

US: Emphasis on injectable-grade traceability and FDA registration drove a preference for established brands but opened new windows for OEM supply. Policy-driven reimbursement rates affect large hospital network purchasing. EU: MDR regime tightened requirements for clinical data and batch-level release. This increased the compliance cost and batch rejection rate for manufacturers. Japan: MOHW sets pricing ceilings for reimbursement. Local production networks face periodic raw material bottlenecks but maintain close control by pharma partners. India: Price-sensitive market grows fastest in volume. Local packagers push for cost reductions but still rely on imports for GMP-grade material. China: Domestic regulatory changes forced local manufacturers to invest in higher-end purification and higher batch audit frequency.

2026 Price Trend Forecast

Market absorption will continue to exceed production scale-up pace. Upward pressure on bioprocess inputs and ongoing regulatory burden sustain a moderate floor under manufacturer ex-works pricing. Price compression due to emerging lower-cost producers is dampened by continued clinical documentation requirements. Full device-grade traceability, customer audit demand, and serialization will maintain tiered price structure between regulated (pharma/medical device) and unregulated (cosmetic, vet) segments. Data suggests possible moderate uptick in 2026, especially for batches requiring new compliance documentation or responding to global raw material interruptions.

Data Sources & Methodology

Forecasts leverage historical sales volumes, announced plant expansions, published regulatory changes, and internal sales order trends. Class III device audit outcomes, regulatory filings, and global shipment logs support real-time capacity status and lead time estimations. Ongoing dialogue with hospital networks and institutional buyers feeds rolling price and demand models.

Industry News & Regulatory Updates

Recent Market Developments

Manufacturers invested in new bioprocess lines to respond to heightened demand for injectable hyaluronic acid in both the OA and aesthetic sectors. Clinical trial reporting requirements rose in Europe with MDR implementation, while US hospitals tightened audits regarding batch traceability and GMP compliance.

Regulatory Compliance Updates

MDR in Europe shifted significant product segments into higher-risk categories, requiring not only batch-level QA but also expanded post-market surveillance. US FDA inspection cycles saw greater intensity, which led to strengthened in-process documentation and new testing methods at the batch release stage. Asian authorities moved to harmonize biopharma API certification with international standards, raising both compliance cost and export potential.

Supplier Response & Mitigation

In response to rising compliance complexity, manufacturing sites installed advanced automated monitoring and upgraded cleanroom capacity. Raw material diversification programs sought to buffer single-source risks. Partnership with controlled logistics providers improved risk management in temperature-controlled shipping. Supplier-customer collaborations advanced joint product registration and shared audit protocols, reducing qualification delays.

HYRUAN Plus Inj. Application Fields & Grade Selection Guide

Application Fields & Grade Matching Guide

Industry Applications

HYRUAN Plus Inj. serves a broad range of uses in pharmaceutical manufacturing, especially in injectable formulations requiring precise molecular weight control, viscosity, and purity. Production batches support use in orthopedic viscosupplementation, ophthalmic surgery, dermatological procedures, and intra-articular therapies. Each application imposes distinct requirements on molecular weight, rheology, trace impurities, and batch consistency.

Grade-to-Application Mapping

Application Recommended Grade Critical Grade Parameters
Orthopedic Viscosupplementation High Molecular Weight Grade Molecular weight distribution, intrinsic viscosity, sterilization residue
Ophthalmic Surgery Ultra-Pure, Low Endotoxin Grade Endotoxin content, transparency, particulate profile
Dermatological Injection Medium-to-High Molecular Weight Purity, molecular weight, protein content, crosslinking ratio (if applicable)
Intra-articular Injection (Non-Orthopedic) Medium Molecular Weight Sterility assurance, rheological steadiness, non-pyrogenicity

Key Parameters by Application

Molecular weight and viscosity drive the main differentiation between grades; orthopedic grades require an upper molecular weight range and controlled polydispersity to deliver lubrication and residence time in the joint. Ophthalmic grades prioritize transparency and lowest possible protein or particulate contamination, demanding higher scrutiny during downstream purification and final filtration. Dermatological applications tolerate a broader molecular weight window but impose stricter limits on protein or nucleic acid impurities to reduce risk of adverse reactions in subdermal tissues.

Sterility, pyrogenicity, and trace metal content are managed batch-wise to ensure the lot meets region-specific regulatory thresholds for the end application. The exact point of control for each impurity or physical characteristic traces back to the raw material batch certificate and in-process controls, which must be tailored per release grade.

How to Select the Right Grade

Step 1: Define Application

Clarify the target formulation, route of administration, and patient population. Ophthalmic and orthopedic intra-articular uses receive stricter quality oversight versus applications where systemic exposure is limited or where the active substance undergoes further downstream processing.

Step 2: Identify Regulatory Requirements

Map relevant pharmacopeial monographs, medical device regulations, or national agency expectations. Differences in accepted endotoxin limits, metal tolerances, or test methodologies arise based on geographic region and end application. Notify both production and QA teams of specific jurisdictional clauses for inspection readiness.

Step 3: Evaluate Purity Needs

Examine allowable impurity profiles and variability by looking at the biofunction and patient safety profile for each target use. High purity, low protein, and low nucleic acid are non-negotiable for injectable ophthalmic and orthopedic products. The risk of inflammatory response increases with trace levels of protein or bacterial breakdown products, which leads the manufacturing route selection and guides in-process purification strategy.

Step 4: Consider Volume & Budget

Balance the cost of higher purity manufacturing, more extensive purification, and smaller batch splitting against volume requirements. Large volume orders allow greater process tightening and dedicated lines, while pilot-scale batches may require blended lots or staggered production windows. Engage with supply planning to assess availability of raw materials on hand and projected inventory timelines.

Step 5: Request Sample for Validation

Use analytical and preclinical test panels to assess chosen HYRUAN Plus Inj. grade performance in real formulation scenarios. Investigate homogeneity, rheological profile, and stability under representative stress conditions. Collate all validation data for internal QA release and external regulatory support files.

Trust & Compliance: Quality Certifications & Procurement Support for HYRUAN Plus Inj.

Quality Compliance & Certifications

Quality Management Certifications

HYRUAN Plus Inj. follows an integrated quality management system anchored in cGMP and ISO standards. Production workflow and internal audits aim for lot-to-lot reproducibility, minimizing batch deviations through rigorous in-process checks. Certification status reflects continual alignment to regulatory inspection requirements across domestic and export markets. Updates to certification are coordinated with regulatory authorities when production processes or material sources change.

Product-Specific Certifications

HYRUAN Plus Inj. aligns its certification portfolio with clinical regulatory pathways and customer end-application needs. For certain regions, dossiers reflect distinct registration, such as medical device or drug product categories depending on market expectations. Approvals and certificates remain valid only within the approved manufacturing site and route. Current certificates are accessible upon official inquiry for authorized channels and may include regional market registrations, cGMP compliance recognitions, and device or pharmaceutical approval notices, as applicable to the supplied grade.

Documentation & Reports

The technical file for HYRUAN Plus Inj. includes full production batch records, control method descriptions, release analytics, and impurity tracking history per regulatory requirements. Development change control, stability studies, raw material supplier qualification, and traceability documentation remain available for qualified purchaser audits. Clinical data, biocompatibility assessments, and safety documentation can be provided on request according to customer procurement process. Data transfer or sharing follows formal confidentiality and regulatory regimen.

Purchase Cooperation Instructions

Stable Production Capacity Supply and Flexible Business Cooperation Plan

Production lines dedicated to HYRUAN Plus Inj. allow for scheduled output planning adapted to both forecast and spot orders. Capacity allocation is based on confirmed purchase intent, historical performance, and risk assessment for market demand fluctuations. Flexible frameworks allow for multi-year procurement contracts, rolling forecasts, and periodic adjustment in minimum order size or delivery frequency to balance customer demand and plant utilization.

Core Production Capacity and Stable Supply Capability

Manufacturing depends on qualified raw material streams and dedicated processing modules. Core production assets are maintained to provide buffer stock and redundancy, mitigating risks from supply chain interruptions. Capacity utilization is monitored against both process yield targets and downtime trends. Lot release cycles, plant scheduling, and warehouse logistics remain coordinated for prompt shipment commitments, especially for long-term supply agreements.

Sample Application Process

Sample requests are processed through an established protocol involving a documented application reviewed by quality assurance. Samples for compatibility or process qualification testing reflect commercial batch history and retain full traceability from production to delivery. Technical staff support the provision of representative product, associated certificates, and formulation or handling guidelines suited for downstream evaluation.

Detailed Explanation of Flexible Cooperation Mode

Cooperation models range from standard spot-purchase to structured partnership agreements. Customers working with variable production plans can utilize consignment, scheduled call-offs, or volume-based tiered pricing. Dedicated technical and account liaisons adjust supply schedules based on forecast updates or unplanned surges, ensuring consistent availability without overstocking. Joint planning for market launches, regulatory submissions, or special project requirements establishes clear deliverable timelines and change management procedures that reflect both operational and compliance needs.

Market Forecast & Technical Support System – HYRUAN Plus Inj.

Research & Development Trends

Current R&D Hotspots

Recent industry R&D prioritizes injectable hyaluronic acid (HA) formulations focused on molecular weight tuning, cross-linking technology improvement, and impurity reduction. Raw material HA, depending on microbial fermentation or animal-derived pathways, influences process contaminants and subsequent purification challenges. Current grade differentiation emerges mostly from varying cross-linking density and the molecular weight profile, which impacts injectability, biological residence time, and rheological stability.

In the production environment, special emphasis is placed on endotoxin and protein removal at each stage to minimize adverse immunological response risk and to meet pharmacopeial criteria for parenteral use. Control points in HA gel manufacturing extend to raw material batch inspection, inline viscosity checks, and moisture reduction steps prior to final sterilization.

Emerging Applications

Most HYRUAN Plus applications remain in the field of osteoarthritis management as viscoelastic supplements for synovial fluid. Newer research targets aesthetic indications and regenerative medicine, especially in markets with evolving regulatory frameworks. The industry is watching closely how HA customization can support localized drug delivery, wound healing matrices, and tissue scaffolds, each with tailored rheological and degradation profiles.

Technical Challenges & Breakthroughs

Endotoxin contamination and batch-to-batch consistency are persistent technical concerns, particularly for high-purity grades. The combination of high viscosity and injectability places stress on filling and sterilization lines, prompting process engineers to optimize mixing and filtration equipment design. Overcoming the tendency of HA gels to shear-thin during processing or injection inspires frequent re-evaluation of cross-linker chemistries and stabilizer inclusion.

Recent process advances include continuous purification modules and enhanced depyrogenation strategies. Analytical upgrades to monitor impurity profiles and cross-linking efficiency enable more reliable release testing tailored to the grade and intended application.

Future Outlook

Market Forecast (3–5 Years)

Demand for HA injectable products continues to grow steadily, driven by both demographic aging and increased procedure frequencies across clinical and aesthetic segments. Regions with progressive reimbursement standards for OA treatment register firmer volume commitments. Grade selection will increasingly depend on tailored mechanical and biological properties matched to local practice preferences.

Ongoing regulatory harmonization in developed and emerging markets may expand the approval basis for novel medical indications, creating demand for adjusted grades with altered cross-linker ratios or drug incorporation.

Technological Evolution

Production strategies are trending towards modular, closed-process setups that reduce contamination risk and support rapid campaign switches for different grade requirements. Manufacturers increasingly validate purification and sterilization sequences against grade-specific bioburden and impurity endpoints, with additional controls for cross-linked or drug-loaded formulations.

Process analytics are moving beyond conventional endpoints to include real-time monitoring of molecular degradation and product rheology, allowing specification adjustment during manufacturing rather than post-process rejection.

Sustainability & Green Chemistry

Raw material sourcing shifts toward non-animal-derived, fermentation-based HA to minimize environmental impact and support broader acceptance in regulated markets. Vendor qualification considers energy and water consumption, and process selection aims to cut solvent use and minimize aqueous waste streams. Manufacturers audit upstream and downstream processes for opportunities to recycle process water and reclaim solvents where permitted.

Technical Support & After-Sales Service

Technical Consultation

Each batch undergoes technical release based on internal and customer-driven specifications. Technical teams address molecular specification queries, grade differentiation advice, and support for custom rheological profiles based on intended device delivery systems. Production, QA, and analytical support jointly resolve deviations and manage regulatory change notifications.

Application Optimization Support

Manufacturer support covers optimization for tailored cross-linker ratios, injectability assessment with clinical teams, and guidance on formulation integrity under anticipated storage and transport conditions. Documentation includes rheological profile stability, microbial control in primary packaging, and strategies for minimizing degradation during handling and downstream formulation.

After-Sales Commitment

Commitment extends to post-release batch traceability and rapid technical response for performance-related complaints or customer-specific test requirements. The technical team engages in deviations investigations, supports record keeping for regulatory audits, and provides updates if process changes affect final product critical quality attributes.

Long-term customer support includes partnership for co-developing new applications within the regulatory boundaries, feedback incorporation into continuous improvement cycles, and transparent sharing of process change impacts on release criteria.

HYRUAN Plus Inj.: Manufacturing Strength for Consistent Industrial Performance

HYRUAN Plus Inj. represents a direct result of focused industrial manufacturing at scale. The process behind this injectable-grade sodium hyaluronate puts full control of quality, traceability, and supply volume in the hands of our production teams, not in the hands of traders or middlemen. Years of chemical engineering and controlled plant operation enable this product to serve specialized industrial buyers that cannot operate with uncertainty or inconsistent inputs.

What We Manufacture

As the direct producer of HYRUAN Plus Inj., we carry out all core stages of production in-house, from fermentation to final fill and pack. Strict process oversight eliminates batch-to-batch variation. The final injectable meets rigorous standards for purity and molecular weight, critical for applications that demand high biocompatibility and precise rheological properties. Every ampoule and vial that leaves our site reflects a managed approach—from raw material qualification to finished packaging.

Key Industrial Applications

The manufacturing design of HYRUAN Plus Inj. targets high-value segments. This includes the medical device industry, health and personal care product formulators, and advanced research labs. Each application sector draws value from a supply chain free of fragmentation—no cut corners, no opaque repackaging. For producers integrating hyaluronate into end-use products like injectables, topical formulations, or device pre-loads, the direct-from-factory channel supports clear specification matching and predictable input cost structures.

Consistent Quality and Production Oversight

Managed quality ranks high among our operational objectives. Every production batch undergoes validated analytical screening to verify molecular weight distribution, endotoxin thresholds, particulate contamination, and other critical release parameters. In-process controls give early warning signals in case of deviation, reducing the risk of non-compliant output. We maintain a documentation trail for each lot, supporting both industrial traceability and downstream regulatory compliance for finished goods manufacturers.

Packaging and Supply Capability

The packaging operation accommodates both small-scale buyers and large-volume demand. We commit to direct shipment from our facilities, utilizing robust packaging lines built to meet strict cleanroom hygiene requirements. Aggregated demand from B2B clients has shaped our logistics operation. Short and reliable supply lead times form the basis of our long-term delivery commitments. Onsite warehousing and cold-chain readiness allow for batch stockpiling, minimizing procurement risk for high-throughput customers.

Technical Support: Direct From Production

We maintain a technical team embedded with our manufacturing unit. Their sole focus is supporting industrial clients before, during, and after purchase. Technical support covers process compatibility, formulation integration, and troubleshooting specific to HYRUAN Plus Inj. in various production environments. First-hand product knowledge gives these teams the tools to solve application-side challenges without need for intermediaries or indirect channels.

Business Value for Manufacturers, Distributors, and Procurement Teams

Direct access to the source of HYRUAN Plus Inj. simplifies procurement and supports leaner operations throughout the supply network. Cost predictability aligns more closely with global market trends, as pricing comes from the point of production—not after fees and margin stacking by unrelated parties. This delivers direct-to-business transparency in contract manufacturing, private label opportunities, and OEM integration. Distributors benefit from guaranteed batch integrity and streamlined documentation, while end users in manufacturing roles find confidence in a supplier that controls the product journey from fermentation tank to packed ampoule.

Aspect Direct Manufacturing Impact
Product consistency In-house controls ensure repeatable quality and predictable physical properties
Supply stability Production and warehousing respond to forecasted B2B contract volumes
Regulatory support Lot traceability and detailed documentation streamline compliance needs
Technical assistance Direct access to technical team attached to production facility

Decades of producing specialty sodium hyaluronate inform our daily commitment to process accountability. HYRUAN Plus Inj. demonstrates the results of that discipline—making consistent product quality, packaging assurance, and scalable supply available to industries that depend on direct input from an engaged and capable manufacturing partner.

Industrial FAQ

What is the molecular composition and concentration of hyaluronic acid in HYRUAN Plus Inj.?

Examining the Source and Purity in Manufacturing

At our manufacturing site, hyaluronic acid used in HYRUAN Plus Inj. comes through a fermentation-based process, ensuring each batch stays free from animal-derived contaminants and aligns with strict quality measures. Our process uses controlled bacterial fermentation, primarily with Streptococcus zooepidemicus, which produces high-purity, non-animal stabilized hyaluronic acid. By refining our extraction and purification protocols, we consistently achieve a product with molecular profiles suitable for intra-articular applications.

Molecular Weight Distribution

Our production lines synthesize and isolate hyaluronic acid with close attention to molecular weight because this characteristic drives the viscoelastic and lubricating properties required for successful viscosupplementation in osteoarthritis. Each batch of HYRUAN Plus Inj. contains hyaluronic acid with a defined molecular weight profile. High molecular weight, generally above 1 million Daltons, supports durability and improved joint lubrication after injection. Regular quality testing using gel permeation chromatography ensures that every lot meets target specifications before packaging and delivery.

Concentration Standards and Clinical Relevance

We fill each syringe of HYRUAN Plus Inj. with a pre-determined concentration of hyaluronic acid in a buffered saline solution. The formulation contains 10 mg of sodium hyaluronate per milliliter, packaged in 2 mL pre-filled syringes for single-dose administration. This concentration has emerged from extensive research and feedback from clinical users seeking optimal synovial supplementation and prolonged residency within the joint space following injection. By providing consistent hyaluronic acid content across every unit, end-users can anticipate a predictable and reliable experience during administration.

Quality Controls and Traceability

Quality assurance teams audit each stage, from raw material selection to final packaging. Every lot passes rigorous assessments for contamination, molecular sizing, and concentration accuracy. We maintain detailed traceability records, from fermentation to the final sterile filling, supporting regulatory compliance and customer confidence. Our stability studies verify that the molecular characteristics and concentration remain unchanged over their shelf life, giving health professionals confidence in performance up to the expiration date.

Commitment to Manufacturing Excellence

We invest in modern production facilities equipped with advanced water-for-injection systems, controlled environments, and validated sterilization cycles. Each line operator receives training to uphold our batch consistency, and our in-house analysts monitor non-conforming results for immediate corrective action. These efforts have enabled us to supply large-scale quantities for distribution in demanding regulatory environments without sacrificing consistency or diminishing raw material purity.

Continuous Improvement and Customer Support

Our development teams continue to monitor the scientific literature, working with practitioners to improve upon our reagents and methods. Feedback about handling, injection characteristics, and post-injection outcomes inform our continuous process optimization. Customers who need technical information or access to typical specifications for hyaluronic acid used in HYRUAN Plus Inj. can expect prompt and detailed support straight from our technical office. This direct approach equips clients with transparency and the assurance they expect from an original manufacturer.

What are the minimum order quantities and lead times for procuring HYRUAN Plus Inj.?

How We Approach HYRUAN Plus Inj. Orders in Our Plant

Every order for HYRUAN Plus Inj. reflects both our commitment to product quality and a responsible approach to manufacturing schedules. As a direct manufacturer, we adopt clear and consistent policies on minimum order quantities and lead times to maintain reliability, product integrity, and compliance in every shipment leaving our facility.

Minimum Order Quantities: Balancing Efficiency with Customer Demand

Producing HYRUAN Plus Inj. at scale helps us achieve consistent quality and allows us to control each step — from procurement of raw hyaluronic acid, through synthesis, filling, sterilization, and final inspection. To maintain these standards, our minimum order quantity is determined by our validated batch size for regulatory and operational efficiencies. By aligning incoming requests with our established production cycles and cleaning validations, we reduce cross-contamination risks and unnecessary downtime, creating a safer and more predictable supply chain for medical-grade injectables.

Large-scale pharmaceutical manufacturing comes with exacting requirements for aseptic processing and environmental control. Smaller orders usually incur much higher unit costs, increased risk of variability, and extra time for changeovers. For these reasons, we establish minimums that reflect both the cost of GMP compliance and the realities of our facility capacity. Direct contract partners typically find our minimums align with best practices for secure and traceable distribution.

Lead Times: Realities Inside a Certified Production Environment

Delivering safe, effective HYRUAN Plus Inj. starts with scheduling. Our raw material sourcing adheres to strict supplier qualifications, traceability, and batch testing protocols. Once we lock in an order, materials undergo release by quality assurance before entering production. The fill-finish process includes multiple in-process controls, sterilization cycles, and comprehensive environmental monitoring — all of which require planned timeframes. Finished products then face mandatory stability and sterility testing before being released to market, in accordance with applicable regulatory submissions and certifications.

Lead times shift based on production load, maintenance shutdowns, and any pending validation activities. Predictability matters, especially for medical applications. We rely on forward planning and ongoing investment in line automation, which helps us shorten turnaround times without compromising adherence to GMP guidelines. Our commitments reflect our daily capacity, regulatory calendar, and logistics network readiness. Details on current production slots and available logistics windows form part of our order negotiation, not afterthoughts to be resolved on the fly.

Order Planning and Partnership

Many of our partners appreciate early engagement — sharing forecasts and collaborating on production schedules ahead of peak demand periods. Our experience shows that transparent planning improves supply chain continuity and helps prevent delays caused by documentation, transport, or customs clearance. By sharing our own capabilities and capacity updates, we tackle problems such as raw material shortages or logistics bottlenecks before they impact hospitals or clinics reliant on HYRUAN Plus Inj.

Meeting regulatory standards while maintaining timely supply means we treat production slots as critical assets. Direct communication with our technical and production teams enables us to answer specific order quantity or lead time questions, backed by documentation and production real-time data. This approach ensures everyone, from procurement to end-user, trusts in every delivered shipment — not just the product but the reliability behind each lot.

What are the storage requirements and international shipping regulations for HYRUAN Plus Inj.?

Understanding Proper Storage

As the direct manufacturer of HYRUAN Plus Inj., we manage storage protocols from the production line through to global distribution hubs. Our teams focus on protecting the molecular stability of the sodium hyaluronate solution contained in each syringe, since temperature and light directly influence its quality.

We keep HYRUAN Plus Inj. at temperatures between 2°C and 8°C. We avoid freezing at all stages, since ice formation can break down the active ingredient and affect viscosity. Refrigeration units at all storage and shipping points run constant monitoring. We regularly calibrate and test these units as part of our internal quality system.

Direct sunlight and fluorescent lighting degrade hyaluronic acid. We store our product in original packaging, designed for minimal light transmission, right after filling and sterilization. Each box of pre-filled syringes leaves our facility with handling instructions printed in multiple languages. Bottlenecks in logistics rarely affect physical storage, since we maintain buffer stocks under strict access control and environment monitoring.

From Packing Room to Airplane: The Logistics Chain

Export compliance sits at our loading docks. Our supply chain specialists track country-specific rules under IATA’s Dangerous Goods requirements and national standards, such as the EU’s GDP (Good Distribution Practice) for pharmaceuticals. HYRUAN Plus Inj. does not fall under hazardous chemicals or pressurized gases, but it does face tight controls regarding cold chain integrity and documentation. We ship only with operators qualified for medicinal product logistics. Our team inspects isothermal shippers and dataloggers so that temperature excursions never compromise product safety.

Each batch receives clear batch identification, manufacture date, and expiration labels per international guidelines. For customs clearance, we register product data dossiers and shipping manifests with destination authorities in advance, ensuring regulatory transparency.

Once customs clears the consignment, destination warehouses must either stock HYRUAN Plus Inj. in dedicated medical-grade refrigerators or distribute it directly to hospitals and clinics. Our after-sales specialists provide guidance to end users concerning in-use stability and transportation from central storage to clinic. Our commitment to traceable, qualified supply chains does not end until the final healthcare provider receives intact product.

Global Shipping Hurdles and Real Solutions

Weather disruptions, refrigeration failures, and port delays remain industry challenges. Our solution is redundancy. Multiple cold storage units operate in parallel in our main depots, and we employ battery-backed portable coolers during airport transfers. Long-haul flights use validated temperature-controlled containers rated for pharmaceuticals. Shipping documentation includes shock and temperature monitoring data, which we review post-arrival to verify handling.

We review changes in international regulations annually, particularly as customs agencies revise criteria for medical device and injectable imports. Each time an importing nation updates electronic traceability or certification requirements, our compliance officers update instructions for each outbound shipment. We support our global distributor network with compliance checklists and emergency contacts in case of any customs issues.

From the granulate preparation to the filling and inspection stage, our manufacturing operations prioritize stable, verified, and regulatory-compliant production and delivery processes. As both the producer and primary exporter of HYRUAN Plus Inj., we keep the focus on quality at every transition point in the supply chain, supporting our partners and ensuring patients receive uncompromised product integrity worldwide.

Technical Support & Inquiry

For product inquiries, sample requests, quotations or after-sales support, please feel free to contact me directly via sales6@ascent-chem.com, +8618018036652 or WhatsApp: +8618018036652